FDA regulatory routes and clinical post-marketing requirements for personalized medicines

被引：0
|
作者：
Vossen, Carla [1 ]
Albano, Jessica [1 ]
Isherwood, Tara [1 ]
机构：
[1] Syneos Hlth, Morrisville, NY USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：229 / 230
页数：2
相关论文
共 50 条
  • [41] Close-to-care Post-marketing Clinical Trials
    Luntz, Steffen P.
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2011, 105 (09): : 637 - 638
  • [42] CLINICAL-TRIALS IN POST-MARKETING SURVEILLANCE OF DRUGS
    BELL, RL
    SMITH, EO
    CONTROLLED CLINICAL TRIALS, 1982, 3 (01): : 61 - 68
  • [43] Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective
    Feltelius, Nils
    Gedeborg, Rolf
    Holm, Lennart
    Zethelius, Bjorn
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2017, 122 (02) : 136 - 147
  • [44] Impact of Scheduled Post-Marketing Safety Summary Analyses on Regulatory Actions
    Sekine, Shohko
    Pinnow, Ellen E.
    Kurtzig, Rebecca
    Wu, Eileen
    Marni, Hall
    Dal Pan, Gerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 443 - 444
  • [45] New Japanese Regulatory Frameworks for Post-Marketing Management of Pharmaceutical Products
    Takamura, Kento
    Tachibana, Keisuke
    Kusakabe, Tetsuya
    Nakai, Kiyohito
    Tsutsumi, Yasuo
    Kondoh, Masuo
    PHARMACEUTICAL RESEARCH, 2020, 37 (07)
  • [46] New Japanese Regulatory Frameworks for Post-Marketing Management of Pharmaceutical Products
    Kento Takamura
    Keisuke Tachibana
    Tetsuya Kusakabe
    Kiyohito Nakai
    Yasuo Tsutsumi
    Masuo Kondoh
    Pharmaceutical Research, 2020, 37
  • [47] Recent Trends in US FDA Post-Marketing Commitments (PMCs) for Pregnancy Safety Studies
    Buus, R.
    Covington, D.
    Veley, K.
    Robinson, M.
    Churchill, P.
    BIRTH DEFECTS RESEARCH, 2020, 112 (11): : 865 - 865
  • [48] FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine
    Roehr, Bob
    BRITISH MEDICAL JOURNAL, 2012, 344
  • [49] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [50] Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System
    Raschi, E.
    Fusaroli, M.
    Forni, M.
    Goldman, A.
    Cicero, A. F. G.
    Poluzzi, E.
    Ponti, F. D.
    DRUG SAFETY, 2022, 45 (10) : 1287 - 1288
12345